BOTHELL, Wash.--(BUSINESS WIRE)--May 10, 2006--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS - News) today announced first quarter 2006 financial results and said that it remains on track to meet 2006 objectives, including: Completing enrollment in the Phase 3 pivotal trial of the Company’s lead product candidate, TOCOSOL® Paclitaxel, in patients with metastatic breast cancer. Collaborating with Sonus’ partner, Schering AG, to initiate additional clinical trials of TOCOSOL Paclitaxel in order to expand global development of the product; and Advancing the Company’s second oncology product candidate, SN2310 Injectable Emulsion, into clinical development.
